logo-loader
RNS
viewReNeuron Group PLC

Grant-funded collaboration with exosome platform

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .au{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 72.0pt 90.0pt;}div.au{}h1.bz{text-indent:117.0pt}span.ca{font-weight:normal}table.cc{margin-left:-5.4pt;border-collapse:collapse}td.bw{width:210.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}span.by{font-family:"Calibri","sans-serif"}span.bx{font-family:"Calibri","sans-serif";background:white}td.bu{width:9.0cm;padding:0cm 5.4pt 0cm 5.4pt} h3.bv{text-align: right}h2.br{text-align: center}span.bs{font-size:12.0pt; font-family:"Calibri","sans-serif"}p.cd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.ce{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.cf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.cg{font-family:"Courier New";font-family:"Calibri","sans-serif"}span.bn{font-family:"Calibri","sans-serif";color:black}span.ch{font-family:"Calibri","sans-serif"}span.aj{} p.ci{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-right: -.05pt; text-align: justify}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:-.05pt;text-align:justify}p.ck{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:1.45pt;text-align:justify}p.cl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.bh{font-size:12.0pt;font-family:"Calibri","sans-serif"}br.bi{page-break-before:always}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold}td.be{width:271.9pt;padding:0cm 5.4pt 0cm 5.4pt}span.bf{font-family: "Calibri","sans-serif"}td.bd{width:116.35pt;padding:0cm 5.4pt 0cm 5.4pt} p.cn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: right}span.bb{font-family:"Calibri","sans-serif"; color:black}p.y,li.y,div.y{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}tr.aw{height:39.35pt}td.ay{width:271.9pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.35pt}p.co{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-top: 12.0pt}p.cp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-bottom:13.5pt}td.ax{width:116.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.35pt}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-right: 1.45pt; text-align: justify} /**/
RNS Number : 9930I
ReNeuron Group plc
14 August 2019
 

 

 

14 August 2019

 

AIM: RENE

 

ReNeuron Group plc

("ReNeuron" or "the Company")

 

Grant-funded collaboration with exosome platform

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron's exosome-based drug delivery technology platform.

 

The grant has been awarded under Innovate UK's Knowledge Transfer Partnership and will fund a £250,000 collaborative programme of research to be undertaken by ReNeuron and the European Cancer Stem Cell Research Institute at Cardiff University.  The research programme will develop novel systems to enable the delivery of therapeutic nucleic acids, such as small interfering RNA (siRNA), across the blood brain barrier using ReNeuron's CTX stem cell-derived exosomes.

 

Delivering therapeutic compounds across the blood brain barrier remains a significant challenge - current delivery methods focus on easier-to-reach areas of the body.  Earlier data generated at ReNeuron have already demonstrated the ability of its CTX-derived exosomes to cross the blood brain barrier.  The ambition of the collaboration between ReNeuron and the University of Cardiff is to open up a new route for the delivery of therapeutic agents that have previously failed to target the brain.

 

Commenting on the grant award, Dr Randolph Corteling, Head of Research at ReNeuron, commented:

 

"We and our collaborators are delighted to have won this latest grant from Innovate UK.  We are very excited about the potential of our exosome technology platform to deliver therapeutic compounds to the brain and thereby to make a real step-change in the development of treatments against hard-to-target disorders of the central nervous system."

 

ENDS



 

Enquiries:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan

 

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham




Stifel Nicolaus Europe Limited

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

N+1 Singer

Aubrey Powell, James Moat, Iqra Amin (Joint Broker)

 

+44 (0) 20 7496 3000

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron can be found at www.reneuron.com.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGUGDISXBBGCS

Quick facts: ReNeuron Group PLC

Price: 136

Market: LSE
Market Cap: £43.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18